lenalidomide has been researched along with dasatinib in 10 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (dasatinib) | Trials (dasatinib) | Recent Studies (post-2010) (dasatinib) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 2,707 | 216 | 2,081 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, J; Ding, X; Elvassore, N; Jiang, B; Kong, Y; Liu, H; Liu, L; Mi, Q; Qiu, X; Ren, C; Shao, Y; Yang, X; Yin, Q; Zhao, Q | 1 |
| Curtiss, FR | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Einsele, H; Jungkunz-Stier, I; Seggewiss-Bernhardt, R; Stühmer, T; Zekl, M | 1 |
| Fan, L; Han, TT; Li, JY; Xu, W | 1 |
| Dusetzina, SB; Keating, NL; Rotenstein, LS | 1 |
| Jiang, ZY; Jin, YH; Lu, MC; Shan, WX; Wang, XY; Wang, Y; You, QD | 1 |
3 review(s) available for lenalidomide and dasatinib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment | 2014 |
7 other study(ies) available for lenalidomide and dasatinib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Topics: Animals; Cell Proliferation; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Half-Life; Humans; K562 Cells; Lenalidomide; Ligands; Mice; Neoplasms; Protein Kinase Inhibitors; Proteolysis; Structure-Activity Relationship; Thalidomide; Transplantation, Heterologous; Ubiquitin-Protein Ligases | 2021 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
Topics: Apoptosis; Cell Degranulation; Cell Line, Tumor; Cell Proliferation; Cytokines; Dasatinib; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lysosomal-Associated Membrane Protein 1; Lysosomal-Associated Membrane Protein 2; Multiple Myeloma; Protein Kinase Inhibitors; Pyrimidines; Thalidomide; Thiazoles; TNF-Related Apoptosis-Inducing Ligand | 2014 |
Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit.
Topics: Adult; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Drug Prescriptions; Female; Health Expenditures; Humans; Imatinib Mesylate; Lenalidomide; Male; Middle Aged; Neoplasms; Prescription Fees; Retrospective Studies; Survival Analysis; Thalidomide; United States; Young Adult | 2018 |
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown.
Topics: Adaptor Proteins, Signal Transducing; Azo Compounds; Cell Line, Tumor; Dasatinib; Fusion Proteins, bcr-abl; Humans; Lenalidomide; Ligands; Proteolysis; Stereoisomerism; Ubiquitin-Protein Ligases; Ubiquitination; Ultraviolet Rays | 2020 |